ReviewInternational braz j urol : official journal of the Brazilian Society of Urology
Biochemical recurrence after radical prostatectomy: what does it mean?
Review in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 4 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- The Role of Artificial Intelligence in the Characterization and Outcome Prediction of Prostate Cancer: A Systematic Review.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- Pooled it
- Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Pooled it
- Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature.Nutrients · 2021Pooled it
- Post-prostatectomy magnetic resonance-guided adaptive salvage radiotherapy: early toxicity and biochemical outcomes from a prospective single center cohort.Clinical and translational radiation oncology · 2026Article
- Oncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer.Clinical and translational radiation oncology · 2026Article
- Prostate Cancer Treatment: Cryoablation in Context.Cancers · 2026Review
- Integrated Single-Cell RNA-Seq and Machine Learning to Construct an EMT Infiltration Scoring Model for Prostate Cancer.International journal of molecular sciences · 2026Article
- Real-world clinical outcomes in patients with biochemical recurrence after local therapy for non-metastatic prostate cancer.Future oncology (London, England) · 2026Observational
- Review
- Early Postoperative PSA Dynamics and Prognostic Implications After Radical Prostatectomy.Cancers · 2026Article
- RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Feasibility and Outcomes of Perirectal Spacer Implantation in Previously Treated Prostate Cancer Patients Undergoing Salvage Proton Therapy Radiation.Advances in radiation oncology · 2026Article
- Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.EJNMMI research · 2026Article
- Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.British journal of cancer · 2026Article
- A Platform-Independent Binary Gene-Pair Signature Derived from CRPC-Enriched Single-Cell Transcriptomics for Predicting Recurrence-Free Survival in Prostate Cancer.Cancer management and research · 2026Article
- Diagnostic performance of conventional MRI using T1W and T2W for primary lymph node staging in intermediate- and high-risk prostate cancer patients prior to pelvic lymph node dissection.Abdominal radiology (New York) · 2026Observational
- Regenerative strategies for post-prostatectomy incontinence: stem cells, exosomes, and the path to clinical resolution.American journal of clinical and experimental urology · 2026Review
- NPRL2 gene expression as a predictor of biochemical recurrence after robot-assisted radical prostatectomy.BMC urology · 2025Article
- Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).Future oncology (London, England) · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadical prostatectomy (RP) has been used as the main primary treatment for prostate cancer (PCa) for many years with excellent oncologic results. However, approximately 20-40% of those patients has failed to RP and presented biochemical recurrence (BCR). Prostatic specific antigen (PSA) has been the pivotal tool for recurrence diagnosis, but there is no consensus about the best PSA threshold to define BCR until this moment. The natural history of BCR after surgical procedure is highly variable, but it is important to distinguish biochemical and clinical recurrence and to find the correct timing to start multimodal treatment strategy. Also, it is important to understand the role of each clinical and pathological feature of prostate cancer in BCR, progression to metastatic disease and cancer specific mortality (CSM). Review design: A simple review was made in Medline for articles written in English language about biochemical recurrence after radical prostatectomy.
objectiveTo provide an updated assessment of BCR definition, its meaning, PCa natural history after BCR and the weight of each clinical/pathological feature and risk group classifications in BCR, metastatic disease and CSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.